03 February 2017: Articles
Adult-Onset Still’s Disease: Still a Serious Health Problem (a Case Report and Literature Review)
Unusual clinical course, Challenging differential diagnosis, Unusual setting of medical care, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Mojgan Agha-Abbaslou ADEF 1, Ana Maria Bensaci BDE 2, Oluchi Dike B 3, Mark C. Poznansky E 1, Arooj Hyat DE 3*DOI: 10.12659/AJCR.901846
Am J Case Rep 2017; 18:119-124
Abstract
BACKGROUND: Adult-onset Still’s Disease (AOSD) is a rare systemic inflammatory disease accompanied by a triad of spiking fever, maculopapular exanthema, and arthralgia. To date, there is no definite laboratory or imaging test available for diagnosing AOSD, and the diagnosis is one of exclusion, which can be very challenging.
CASE REPORT: We report on the case of a 53-year-old female who presented with fever, arthralgia, and abdominal pain. Her initial laboratory tests showed elevated AST and ALT, and normal leukocytes with bandemia. During her hospitalization, we evaluated the patient for other potential differential diagnoses. After an extensive workup, the patient was diagnosed with AOSD based on Yamaguchi criteria. Her serum ferritin levels were measured and found to be markedly elevated, which is a non-specific finding in AOSD patients.
CONCLUSIONS: This case highlights the important role of a detailed history and physical examination for timely diagnosis of AOSD to prevent complications and improve patient’s prognosis.
Keywords: Abdominal Pain, Arthralgia, Exanthema, Ferritins, Still's Disease, Adult-Onset
Background
In 1897, Dr. Still evaluated 22 children with arthritis in the UK and named the condition “juvenile rheumatoid arthritis” [1]. In 1971, Dr. Bywaters evaluated 14 adult patients with clinical manifestations resembling juvenile rheumatoid arthritis: macular rash, joint pain, and spiking fever [2]. This triad is now known to be characteristic of Adult-onset Still’s Disease (AOSD). However, to date, there is no definite laboratory or imaging test available for diagnosing AOSD. Serum ferritin levels in AOSD patients are usually elevated, which is thought to be associated with cytokines dysregulation [3]. AOSD is an exclusion diagnosis; clinician’s with a suspicion of AOSD, must rule out other medical conditions with similar manifestations including autoimmune diseases [4].The treatment for AOSD includes anti-inflammatory agents (non-steroid anti-inflammatory drugs (NSAIDs) and corticosteroids), immune-suppressants, and rheumatologic agents (methotrexate, azathioprine, tacrolimus, and cyclosporine). Intravenous immunoglobulins (IVIGs) could be used to treat an acute AOSD presentation [5]. Anti TNF-α and anti-interleukins have also been shown to be beneficial in treatment of refractory AOSD [6,7].
Case Report
A 53-year-old female, originally from Puerto Rico, was admitted to our community hospital after experiencing spiking fevers with maximum temperature of 103°F (39.4°C) for more than two weeks, accompanied with loose stools, abdominal pain, decreased appetite, and generalized joint pain. The patient had a past medical history that was significant for anxiety, depression, type 2 diabetes, nodular goiter, dyslipidemia, gastroesophageal reflux disease (GERD), asthma, and fibromyalgia. She also reported experiencing some pruritic non-blanching rashes over the flexor aspect of both upper extremities as well as the medial aspect of her thighs a week prior to admission, which had resolved spontaneously. She denied any headaches, runny nose, cough, or shortness of breath. The patient lived alone, had no pets, and did not work. She was a former smoker but denied any alcohol or drug abuse. There was no history of incarceration or homelessness.
Upon admission, she was stable, and her temperature was 99.5°F (37.5°C). On physical examination, she had an enlarged spleen which was painful on palpation; splenomegaly was later confirmed by an imaging study (CT-scan). Her initial hematologic tests showed normal WBC count with bandemia (24.5%). Serum BUN and creatinine (Cr) levels were slightly elevated compared with her baseline values (13, 1.09 mg/dL
Since the patient was diabetic and obese (BMI >30 kg/m2), and her prominent complaint was abdominal pain, surgical consultation was done to rule out cholecystitis, diverticulitis, and other surgical related conditions. Also, broad-spectrum empiric antibiotic therapy was started for the patient, given a concern for intra-abdominal infection. Colonoscopy was performed as part of the abdominal pain evaluation and demonstrated a small polyp in the transverse colon which was excised. There was no evidence of any diverticulitis.
During hospitalization, the patient experienced intermittent high fevers (>39.4oC) and her rashes reappeared, so our hospital infectious disease specialist re-evaluated her. This time, on physical examination, she had multiple non-blanching salmon colored rashes over her left thigh as well as arthritis in her fingers with swollen interphalangeal joints. On further history investigation, the patient reported experiencing a sore throat a week before initiation of other symptoms.
Given the new findings in her history, persistent fever, arthritis, and rashes, the possibility of AOSD was raised and serum ferritin levels were ordered; and revealed highly elevated levels (2,723 ng/mL). We discontinued the empiric antibiotics and started prednisone (20 mg twice a day) for the patient. Subsequently, her joint pain began to improve. However, she continued experiencing fever (102.2°F, 39°C). The patient was then referred to another institute for further rheumatology investigation and workup, where a PET scan showed diffuse supraclavicular, mediastinal, and hilar lymphadenopathy. An excisional cervical lymph node biopsy revealed reactive lymphadenopathy. These new findings confirmed our diagnosis of AOSD. The patient’s symptoms started to improve by the time the biopsy was performed. Prednisone was held and a six-week follow-up was recommended.
Discussion
EPIDEMIOLOGY:
Adult-onset Still’s disease (AOSD) is a rare disease. There are few published data available regarding its incidence and prevalence in different populations. In 2009, Owlia et al. from Iran reviewed more than 1,000 PubMed titles and reported that the crude prevalence of AOSD was 1.5 cases in 100,000–1,000,000. In the same review, the age of AOSD onset had a bimodal range with two group: 15–25 and 36–46 years of age [8]. In 1997, Wakai et al. from Japan reviewed 125 cases of Japanese patients with AOSD and reported the female to male ratio was 2.1 [9]. In a 2009 retrospective study, 84 Turkish patients were evaluated, and 70.2% of them were female versus 29.8% male. The investigators concluded that AODS affects women more than men [10]. In 2015, the demographic features, clinical manifestations, and laboratory tests of 75 Chinese patients with AOSD were studied and the age range at the time of AOSD onset was reported to be 16–82 years with the median age of 35.75±13.25 years, and women were more affected than men (44 vs. 31) [11].
PATHOGENESIS:
The pathogenesis of AOSD is not clear. Several factors have been suggested to contribute to the disease occurrence, including genetics, viral and bacterial infections, and immune dysfunction [12–15]. A number of studies reported an important role for interleukins (IL-1, IL-6, and IL-18), macrophage colony stimulating factor, interferon gamma (INF-γ), and tumor necrosis factor alpha (TNF-α) in AOSD pathogenesis [16–19]. In a recent study performed in South Korea, serum levels of CXCL10 and CXCL13 in 39 patients with active AOSD were significantly higher than in patients with rheumatoid arthritis and healthy people [20]. The investigators concluded that serum levels of CXCL10 and CXCL13 might be useful markers to assess AOSD activity.
CLINICAL MANIFESTATIONS:
AOSD is a systemic inflammatory disease accompanied by spiking fever, sore throat, arthralgia, rash, and hepatosplenomegaly. However, some patients may present only with fever. These patients may then go under evaluations for fever of unknown origin (FUO) [21]. In addition to fever, our patient had a mild sore throat a week prior to her admission to our institution. Some studies have shown that pharyngitis could be an initial manifestation in AOSD [22,23]. Another characteristic of AOSD is salmon colored macular or maculopapular rash. The rash may be pruritic in its nature [24]. Another form of rash seen in AOSD is an urticarial eruption on the flexor surface of limbs or trunk [24–27]. Some studies reported that any cutaneous stimuli such as a scratch test could lead to an exaggerated urticarial response in patients with AOSD [28]. Our patient had a history significant for pruritic maculopapular rashes but was presented with fever, abdominal pain, and generalized joint pain. While she was hospitalized for further evaluation, the rash reappeared and she experienced arthralgia in multiple joints with interphalangeal joints more likely to be involved.
Joint pain (arthralgia) is another symptom of AOSD. In one study in Thailand, 16 cases with AOSD were reviewed and all of them had arthralgia (100%) [29]. In contrast, reviewing 75 cases with AOSD in China showed less incidence for arthralgia when compared with five other case reviews (57.3% in China vs. 96.4% in Turkey, 79% in Italy, 88.8% in France, and 97.5% in Spain) [11].
Our patient also presented with abdominal pain and on physical examination experienced tenderness on palpation over her spleen. Interestingly, although abdominal pain is considered to be one of the non-specific symptoms in AOSD, we only found one study reported it in 50% of the Japanese patients with AOSD [30]. Splenomegaly is another non-specific sign of AOSD. In a study by Liu et al., only 14 out of 72 patients (18.6%) with AOSD had splenomegaly [11]. Reactive hemophagocytic syndrome (RHS) is another life-threatening complication of AOSD. Fever, pancytopenia, liver dysfunction, coagulopathy, and neurologic symptoms are characteristics of RHS. In a retrospective study in South Korea, 109 cases with AOSD (21 patients with both RHS and AOSD) were evaluated for splenomegaly (from 1996 to 2013). Of those with AODS and RHS, 11 patients had splenomegaly (52%). In contrast, only 17 patients out of 88 patients with AOSD alone had splenomegaly (19.3%) [31]. Our patient had splenomegaly, elevated liver enzymes (AL and AST), and fever as positive signs for RHS but no pancytopenia and neurological symptoms. Other less common manifestations of AOSD include hepatomegaly [11,32,33], pneumonia and pleuritis [34], thrombotic thrombocytopenic purpura (TTP) [35], and cardiac involvement (pericarditis and tamponade) [36].
LABORATORY AND IMAGING FINDINGS:
Laboratory findings in AOSD are similar to those in other inflammatory processes, with the most common abnormalities being: leukocytosis (mostly neutrophils), anemia, elevated ferritin, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and abnormal liver function tests (AST and ALT) [31,37,38]. Among the laboratory abnormalities, serum ferritin levels are reported to be five times or more above the upper normal limits (usually >1,000 ng/mL in most cases) which is thought to be related to cytokines release [3]. Although some studies consider it as a diagnostic tool for AOSD [37,39], markedly elevated ferritin is not significant to AOSD. Other causes of highly elevated ferritin include systemic juvenile idiopathic arthritis and macrophage activation syndrome (MAS) [40]. Ferritin has several isoforms. Glycosylated ferritin is an isoform of ferritin which is generally low in patients with AOSD. In a retrospective study in 2001, serum ferritin and glycosylated ferritin levels of 49 patients with AOSD were compared with 120 controls. Patients with AOSD had significantly higher values of serum ferritin (4,752±9,599 vs. 1,571±3,807 ng/mL, p<0.05). In contrast, serum glycosylated ferritin levels were significantly lower in AOSD patients when compared with controls (15.9±11.9% vs. 31.5±18.7%, p<0.001) [39]. Our patient’s serum ferritin levels were markedly elevated (2,723 ng/mL). We did not measure her serum glycosylated ferritin levels. As in our case, ANA and RF have also been reported to be negative in patients with AOSD [41].
Imaging studies are usually unremarkable in patients with AOSD except for progressive erosions and narrowing joint space [41–43] and hepatosplenomegaly [43,44].
CLASSIFICATION:
In 1992, Yamaguchi introduced his criteria for AOSD diagnosis and classification [4]. This criteria has been validated and reported to be the most sensitive criteria (93.5%) compared to Calabro, Cush, and Reginato criteria [45,46].
Yamaguchi criteria is divided into major and minor criteria: Major criteria: Fever of 39°C or higher (≥1 week). Arthralgia (≥2 weeks). Salmon colored maculopapular rash. Leukocytosis (≥10,000/µL with ≥80% granulocytes).
Minor criteria: Sore throat. Lymphadenopathy and/or splenomegaly. Liver dysfunction. Negative rheumatoid factor (RF) and antinuclear antibody (ANA) tests.
Five features of Yamaguchi criteria, including at least two major criteria, must be present for AOSD diagnosis. Our patient had three major features of Yamaguchi criteria: fever, arthralgia, and rash. She also met three features of Yamaguchi minor criteria: history of a sore throat, splenomegaly, and negative RF and ANA.
There are a number of diseases that need to be excluded in the Yamaguchi classification before the diagnosis for AOSD can be made:Infections: infective endocarditis, hepatitis B and C, rubella, HIV, cytomegalovirus, coxsackie, tuberculosis, and Lyme disease.Malignancies: hematologic (lymphoma, leukemia), solid tumors (breast and lung cancers mostly), and melanoma [47].Vasculitis: polyarteritis nodosa (PAN), granulomatosis with polyangiitis (Wegner’s granulomatosis), and Takayasu’s arteritis.Connective tissue diseases: systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)
We evaluated our patient for infections: tuberculosis, malaria, babesia, isospora, cyclospora, giardia, salmonella, HAV/HBV/ HCV, CMV, EBV, typhoid, Lyme disease, ehrlichia, HIV, chlamydia, gonorrhea, syphilis, rotavirus, Yersinia, and campylobacter infections; all were unrevealing.
Biopsy of lymph nodes, stomach, colon, and thyroid nodule in our patient were unremarkable for malignancies. Hepatobiliary (HIDA) scan showed normal radiotracer distribution throughout the liver, common bile duct, and small bowel. Transthoracic echocardiography (TTE) was unremarkable for infective endocarditis. Immunostaining of the cervical lymph node specimen did not reveal any IgG4 related changes. Taken together, the immunostaining along with the flow cytometry results showed a reactive process. No granulomas or malignancy changes were seen.
Since the patient’s fever, arthralgia, rash, and lymphadenopathy were improved significantly after several days of hospitalization and she was willing to leave the hospital, we recommended that she follows up for further dermatologic and rheumatologic evaluation. In the meanwhile, we made the AOSD diagnosis based on the Yamaguchi criteria which is, to our knowledge, the most sensitive criteria available for AOSD diagnosis.
TREATMENT:
AOSD treatment is based on anti-inflammatory medications, including steroids, NSAIDs, and anti-rheumatic agents to control symptoms such as fever, joint pain, and systemic inflammation [5]. Two studies showed that NSAIDs alone are not effective to control AOSD symptoms in 4–82% of patients. In those studies, 20% of patients complained of adverse effects [48,49]. Corticosteroids are reported to be effective in approximately 65% of patients [50] with greater efficacy in systemic AOSD [49], while methotrexate and other anti-rheumatic agents (DMARDs) control the disease in 40–70% of the steroid-dependent AOSD cases [49]. Some retrospective studies suggest that cyclosporine is as effective as methotrexate in systemic AOSD [49,50]. Cyclosporine could be used in patients with severe AOSD as well as patients with microphage activation syndrome (MAS) [50–52]. MAS is a complication of AOSD which is thought to be caused by long-standing hyperactivity of immune system with dysregulated CD8+T cells and macrophages expansion [51,52].
Anti-interleukin 1 (IL-1Ra and anakinra) [38], anti-interleukin 6 (tocilizumab) [53], anti- IL1β (canakinumab) [54], and TNF-α inhibitors (infliximab, etanercept, and adalimumab) [55] are other newly developed biological treatments which have been shown to be effective in refractory AOSD [6,7]. Overall, either monotherapy or combination therapy can be used to treat AOSD based on the disease course and symptoms severity.
PROGNOSIS:
AOSD is a disease with a number of distinct clinical patterns, each with significant prognostic consequences [41,43,56]:The disease can be self-limited (monocyclic) in nature. This pattern is characterized by fever, rash, and organomegaly. Remission happens within one year from the onset of the first (and last) episode of the disease.The disease may have an intermittent (polycyclic systemic) pattern with several flare-up episodes with or without joint involvement. Patients may experience a complete remission between the flares and episodes may be several years apart and/or tend to be milder than the initial episode.The disease may have a chronic articular pattern. In this pattern, the articular manifestations (joint involvements) are dominant and may range from mild to severe symptoms which may lead to joint destruction.
In general, patients with only localized disease have a better prognosis compared to those with more disseminated disabilities and/or severe complications such as pericarditis, diffuse intravascular coagulation (DIC), and liver and respiratory failure.
Conclusions
AOSD is an exclusion diagnosis which can be very challenging. It needs an extensive workup and multidisciplinary evaluation to rule out infections and hematologic-oncologic processes. Since the disease has a number of life-threatening complications, a detailed history and physical examination are needed for patients with FUO when there is a suspicion for AOSD to prevent complications and improve the prognosis. Our patient experienced a flare-up with her rash reappearing and interphalangeal joints involvement while she was under evaluation for fever and abdominal pain. This suggests that caregivers should be aware of newly developed symptoms and/or signs in hospitalized patients in order to address them properly and on time.
On the other hand, despite having access to many imaging technologies these days, a detailed history and a good physical examination are still two powerful tools which can guide us through an accurate diagnosis.
More clinical studies could be useful to increase our knowledge about AOSD and guide us through tailoring more effective therapies.
References:
1.. Middlemiss JH, Juvenile rheumatoid arthritis (Still’s disease): Proc R Soc Med, 1951; 44(5); 805-16, pmid: 14891783
2.. Bywaters EG, Still’s disease in the adult: Ann Rheum Dis, 1971; 30(2); 121-33, pmid: 5315135
3.. Mehta B, Efthimiou P, Ferritin in adult-onset Still’s disease: Just a useful innocent bystander?: Int J Inflamm, 2012; 2012; 298405
4.. Yamaguchi M, Ohta A, Tsunematsu T, Preliminary criteria for classification of adult Still’s disease: J Rheumatol, 1992; 19(3); 424-30, pmid: 1578458
5.. Kim HA, Sung JM, Suh CH, Therapeutic responses and prognosis in adult-onset Still’s disease: Rheumatol Int, 2012; 32(5); 1291-98, pmid: 21274538
6.. Kokkinos A, Iliopoulos A, Greka P, Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients: Clin Rheumatol, 2004; 23(1); 45-49, pmid: 14749983
7.. Naniwa T, Tamechika S, Iwagaitsu S, Successful use of higher-dose etanercept for multirefractory systemic flare of adult-onset Still’s disease with liver failure with no response to tocilizumab therapy: Case Report Rheumatol, 2013; 2013; 923497
8.. Owlia MB, Mehrpoor G, Adult-onset Still’s disease: A review: Indian J Med Sci, 2009; 63(5); 207-21, pmid: 19584494
9.. Wakai K, Ohta A, Tamakoshi A, Estimated prevalence and incidence of adult Still’s disease: Findings by a nationwide epidemiological survey in Japan: J Epidemiol, 1997; 7(4); 221-25, pmid: 9465547
10.. Cagatay Y, Gul A, Cagatay A, Adult-onset Still’s disease: In J Clin Pract, 2009; 63(7); 1050-55
11.. Liu Z, Lv X, Tang G, Clinical features and prognosis of adult-onset Still’s disease: 75 cases from China: Int J Clin Exp Med, 2015; 8(9); 16634-39, pmid: 26629195
12.. Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ, Adult onset Still’s disease and viral infections: Ann Rheum Dis, 1988; 47(9); 764-67, pmid: 3178317
13.. Efthimiou P, Moorthy LN, Mavragani CP, Adult onset Still’s disease and autoinflammation: Int J Inflam, 2012; 2012; 964751, pmid: 22988543
14.. Escudero FJ, Olen V, De Sevilla TF, Sellas A, Rubella infection in adult onset Still’s disease: Ann Rheum Dis, 2000; 59(6); 493
15.. Perez C, Artola V, Adult Still’s disease associated with Mycoplasma pneumonia infection: Clin Infect Dis, 2001; 32(6); E105-6, pmid: 11247732
16.. Chen DY, Lan JL, Lin FJ, Hsieh TY, Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease: J Rheumatol, 2004; 31(11); 2189-98, pmid: 15517632
17.. Giampietro C, Ridene M, Lequerre T, Anakinra in adult-onset Still’s disease: Long-term treatment in patients resistant to conventional therapy: Int J Inflam, 2013; 65(5); 822-26
18.. Priori R, Colafrancesco S, Alessandri C, Interleukin 18: A biomarker for differential diagnosis between adult-onset Still’s disease and sepsis: J Rheumatol, 2014; 41(6); 1118-23, pmid: 24786926
19.. Fautrel B, Sibilia J, Mariette X, Combe B, Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases: Ann Rheum Dis, 2005; 64(2); 262-66, pmid: 15184196
20.. Han JH, Suh CH, Jung JY, Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease: Arthritis Res Ther, 2015; 17; 260, pmid: 26385705
21.. Mert A, Ozaras R, Tabak F, Fever of unknown origin: A review of 20 patients with adult-onset Still’s disease: Clin Rheumatol, 2003; 22(2); 89-93, pmid: 12740670
22.. Nguyen KH, Weisman MH, Severe sore throat as a presenting symptom of adult onset Still’s disease: A case series and review of the literature: J Rheumatol, 1997; 24(3); 592-97, pmid: 9058672
23.. Jira M, Sekkach Y, Amezyane T, Ghafir D, Adult-onset Still’s disease presenting as retropharyngeal abscess: Eur Ann Otorhinolaryngol Head Neck Dis, 2015; 132(4); 245-46, pmid: 26065822
24.. Kikuchi N, Satoh M, Ohtsuka M, Yamamoto T, Persistent pruritic papules and plaques associated with adult-onset Still’s disease: Report of six case: J Dermatol, 2014; 41(5); 407-10, pmid: 24628100
25.. Michailidou D, Shin J, Forde I, Typical evanescent and atypical persistent polymorphic cutaneous rash in an adult Brazilian with Still’s disease: A case report and review of the literature: Auto Immun Highlights, 2015; 6(3); 39-46, pmid: 26423534
26.. Nataraja C, Griffiths H, Atypical cutaneous manifestations in adult onset Still’s disease: Case Report Rheumatol, 2016; 2016; 4835147
27.. Setterfield JF, Hughes GR, Kobza Black A, Urticaria as a presentation of adult Still’s disease: Br J Dermatol, 1998; 138(5); 906-8, pmid: 9666847
28.. Mehrpoor G, Owlia MB, Soleimani H, Ayatollahi J, Adult-onset Still’s disease: A report of 28 cases and review of the literature: Mod Rheumatol, 2008; 18(5); 480-85, pmid: 18754076
29.. Louthrenoo W, Aramsareewong T, Sukitawut W, Adult onset Still’s disease: Clinical features and outcome in 16 Thai patients: J Clin Rheumatol, 2001; 7(5); 301-7, pmid: 17039160
30.. Hashimoto M, Shingu M, Ezaki I, Clinical studies on 14 cases of adult-onset Still’s disease: Nihon Rinsho Meneki Gakkai Kaishi, 1995; 18(1); 45-52, pmid: 7553038
31.. Bae CB, Jung JY, Kim HA, Suh CH, Reactive hemophagocytic syndrome in adult-onset Still disease: Clinical features, predictive factors, and prognosis in 21 patients: Medicine (Baltimore), 2015; 94(4); e451, pmid: 25634183
32.. Appenzeller S, Castro GR, Costallat LT, Adult-onset still Disease in Southeast Brazil: J Clin Rheum, 2005; 11(2); 76-80
33.. Fujikawa A, Hosoai H, Tamura T, Naoi Y, Serial Ga-67 scintigraphic findings of adult onset Still’s disease: Clin Nucl Med, 2004; 29(6); 372-74, pmid: 15166886
34.. Ak O, Ozer S, Cağ Y, Karagöz G, An adult onset Still’s disease mimicking pneumonia: Rheum Int, 2012; 32(8); 2539-41
35.. Gopal M, Cohn CD, McEntire MR, Alperin JB, Thrombotic thrombocytopenic purpura and adult onset Still’s disease: Am J Med Sci, 2009; 337(5); 373-76, pmid: 19322066
36.. Drouot MH, Hachulla E, Houvenagel E, [Cardiac complications in adult onset Still disease: From pericarditis to tamponade as manifestations]: Rev Med Interne, 1994; 15(11); 740-73, pmid: 7846389 [in French]
37.. Meijvis SC, Endeman H, Geers AB, ter Borg EJ, Extremely high serum ferritin levels as diagnosis tool in adult onset still’s disease: Netherlands J Med, 2007; 65(6); 212-14
38.. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Efficacy of anakinra in refractory adult-onset Still’s disease: Multicenter study of 41 patients and literature review: Medicine, 2015; 94(39); e1554, pmid: 26426623
39.. Fautrel B, Le Moël G, Saint-Marcoux B, Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease: J Rheumatol, 2001; 28(2); 322-29, pmid: 11246670
40.. Moore C, Ormseth M, Fuchs H, Causes and significance of markedly elevated serum ferritin levels in an academic medical center: J Clin Rheumatol, 2013; 19(6); 324-28, pmid: 23965472
41.. Efthimiou P, Paik PK, Bielory L, Diagnosis and management of adult onset Still’s disease: Ann Rheum Dis, 2006; 65(5); 564-72, pmid: 16219707
42.. Björkengren AG, Pathria MN, Sartoris DJ, Carpal alterations in adult-onset Still disease, juvenile chronic arthritis, and adult-onset rheumatoid arthritis: Comparative study: Radiology, 1987; 165(2); 545-48, pmid: 3659381
43.. Gopalarathinam R, Orlowsky E, Kesavalu R, Yelaminchili S, Adult onset Still’s disease: A review on diagnostic workup and treatment options: Case Rep Rheumatol, 2016; 2016; 6502373, pmid: 27042373
44.. Zhu G, Liu G, Liu Y, Liver abnormalities in adult onset Still’s disease: A retrospective study of 77 Chinese patients: J Clin Rheumatol, 2009; 15(6); 284-88, pmid: 19734733
45.. Kumar S, Kunhiraman DS, Rajam L, Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA): Pediatr Rheumatol Online J, 2012; 10(1); 40, pmid: 23176399
46.. Jiang L, Wang Z, Dai X, Jin X, Evaluation of clinical measures and different criteria for diagnosis of adult-onset Still’s disease in a Chinese population: J Rheumatol, 2011; 38(4); 741-46, pmid: 21285163
47.. Liozon E, Ly KH, Vidal-Cathala E, Fauchais AL, Adult-onset Still’s disease as a manifestation of malignancy: Report of a patient with melanoma and literature review: Rev Med Interne, 2014; 35(1); 60-64, pmid: 24094701
48.. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Adult-onset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients: Medicine (Baltimore), 2014; 93(2); 91-99, pmid: 24646465
49.. Franchini S, Dagna L, Salvo F, Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease: Arthritis Rheum, 2010; 62(8); 2530-35, pmid: 20506370
50.. Mitamura M, Tada Y, Koarada S, Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease: Mod Rheumatol, 2009; 19(1); 57-63, pmid: 18839270
51.. Mehta MV, Manson DK, Horn EM, Haythe J, An atypical presentation of adult-onset Still’s disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: A case-based review of the literature: Pulm Circ, 2016; 6(1); 136-42, pmid: 27162622
52.. Lenert A, Yao Q, Macrophage activation syndrome complicating adult onset Still’s disease: A single center case series and comparison with literature: Semin Arthitis Rheum, 2016; 45(6); 711-16
53.. Puéchal X, DeBandt M, Berthelot JM, Tocilizumab in refractory adult Still’s disease: Arthritis Care Res (Hoboken), 2011; 63(1); 155-59, pmid: 20740616
54.. Kontzias A, Efthimiou P, The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still’s disease: Semin Arthritis Rheum, 2015; 42(2); 201-5
55.. Dechant C, Schauenberg P, Antoni CE, Longterm outcome of TNF blockade in adult-onset Still’s disease: Dtsch Med Wochenschr, 2004; 129(23); 1308-12, pmid: 15179590
56.. Pouchot J, Sampalis JS, Beaudet F, Adult Still’s disease: Manifestations, disease course, and outcome in 62 patients: Medicine (Baltimore), 1991; 70(2); 118-36, pmid: 2005777
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






